Cancer Research Cancer Epigenetics  Genetics and Biology of Brain Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 36, 4525-4529, December 1, 1976]
© 1976 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Coombs, M. M.
Right arrow Articles by Kissonerghis, A.-M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Coombs, M. M.
Right arrow Articles by Kissonerghis, A.-M.

Evaluation of the Mutagenicity of Compounds of Known Carcinogenicity, Belonging to the Benz[a]anthracene, Chrysene, and Cyclopenta[a]phenanthrene Series, Using Ames's Test

Maurice M. Coombs, Cynthia Dixon and Anna-Maija Kissonerghis

Departments of Cell Regulation [C. D.] and Chemistry [M. M. C, A-M. K.], Imperial Cancer Research Fund Laboratories, Lincoln's Inn Fields, London WC2A 3PX, England

Fifty-four polycyclic compounds, 29 of the cyclopenta[a]phenanthrene series, 11 chrysenes, and 14 benz[a]anthracenes, have been tested for mutagenicity by Ames's method, using Salmonella typhimurium TA100. Without exception all 37 carcinogens and a known initiator were mutagens. Of the 16 noncarcinogens 7 were mutagenic, but none of these has yet been tested for initiating, as opposed to carcinogenic, activity. There appeared to be little quantitative correspondence between carcinogenic and mutagenic potency, however, and possible reasons for this are discussed. The aryl hydrocarbon hydroxylase inhibitor 7,8-benzoflavone strongly inhibited the mutagenicity of certain compounds when it was added to the incubations.

Received 6/ 8/76. Accepted 8/30/76.




This article has been cited by other articles:


Home page
Toxicol Ind HealthHome page
M.M. Mumtaz, J.D. George, K.W. Gold, W. Cibulas, and C.T. Derosa
Atsdr Evaluation of Health Effects of Chemicals. Iv. Polycyclic Aromatic Hydrocarbons (PAHs): Understanding a Complex Problem
Toxicology and Industrial Health, November 1, 1996; 12(6): 742 - 971.
[Abstract] [PDF]


Home page
ScienceHome page
N. K. HOOPER, R. H HARRIS, and B. N AMES
Chemical carcinogens
Science, February 16, 1979; 203(4381): 602 - 603.
[PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1976 by the American Association for Cancer Research.